

# Guard Therapeutics appoints Redeye as financial advisor in the strategic review

**Guard Therapeutics (publ) ("Guard" or the "Company") announces today that Redeye Aktiebolag ("Redeye") has been appointed as financial advisor in connection with the strategic review announced by the Company in its press release dated 4 December 2025. The review includes an assessment of potential strategic alternatives, including the identification of possible counterparties for a merger or a reverse acquisition.**

Redeye will assist the Company by providing independent financial advice and analysis with the aim of evaluating those alternatives deemed most appropriate for strengthening the Company's future development and creating long-term value for its shareholders.

The process is in an early stage, and there can be no assurance at this time that the review will result in any specific transaction proposal. The Company's Board of Directors intends to keep the market informed of material developments in the process on an ongoing basis.

For further information, please contact:

## **Guard Therapeutics**

*Tobias Agervald, CEO*

*Telefon: +46 8 670 65 51*

*E-post: [info@guardtherapeutics.com](mailto:info@guardtherapeutics.com)*

## **Redeye**

*Carolina Lönn, Advisor*

*Telefon: +46 76 492 50 94*

*E-post: [carolina.lonn@redeye.se](mailto:carolina.lonn@redeye.se)*

## **About Guard Therapeutics**

Guard Therapeutics is a Swedish clinical-stage biotechnology company that identifies and develops new therapies for diseases with a large unmet medical need, focusing on different forms of kidney disease. The company's candidate drugs are based on the endogenous protein alpha-1-microglobulin. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm (ticker: GUARD).

Certified Adviser is Redeye AB, [Certified Adviser - Redeye](#).

Press Release  
08 December 2025 16:00:00 CET



---

## Attachments

---

[Guard Therapeutics appoints Redeye as financial advisor in the strategic review](#)